Managing side effects of new EGFR lung cancer treatments
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether extra care to prevent skin and infusion side effects helps people with advanced lung cancer who are getting amivantamab (with lazertinib or chemotherapy). It aims to make these treatments easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer with an EGFR mutation (like exon 19 deletion or L858R, or exon 20 insertion).
- You have not had treatment for advanced disease yet, or you have progressed after a previous EGFR inhibitor and are starting second-line treatment.
- You are fit enough for daily activities (Eastern Cooperative Oncology Group performance status 0 or 1).
- If you have brain metastases, they must be stable or already treated and not requiring steroids.
- You agree to follow extra skin care and infusion reaction prevention steps during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (Becotatug vedotin and Pucotenlimab), with or without radiation, as the first treatment for advanced lung cancer that has a specific protein marker (EGFR). The goal is to see if this combination can shrink tumors and help people live longer without their cancer growing.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This study tests two combinations of drugs to see which works better for people with a specific type of lung cancer that has a change in the EGFR gene. The treatments may help shrink tumors or slow their growth.
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.